Search results with tag "Ramucirumab"
肝臓・胆道・膵臓がん の薬物療法
www.gakkai-net.comREACH-2 2nd* 197 Ramucirumab 4.6% 59.9% 2.8 M 8.5 M 95 Placebo 1.1% 38.9% 1.6 M 7.3 M CELESTIAL 2nd 470 Cabozantinib 4% 64% 5.2 M 10.2 M 237 Placebo 0.4% 33% 1.9 M 8.0 M 分子標的薬に関する主な臨床試験 * AFP ≥ 400 ng/ml
Therapeutic Antibodies for the Treatment of Cancer: Cancer ...
ksbbj.or.krRamucirumab (CYRAMZA ) Extracellular domain of VEGF receptor 2 Inhibit angiogenesis 2014 Fully humanized monoclonal antibody, human IgG1. 110 Korean Society for Biotechnology and Bioengineering Journal 35(2): 105-119 (2020) 2.2. - (Antibody-Drug Conjugate, ADC)
Clinical Practice Guidelines in Oncology (NCCN Guidelines ...
www2.tri-kobe.orgBevacizumab, cetuximab, panitumumab, irinotecan, ziv-aflibercept, ramucirumab, regorafenib, trifluridine + tipiracil, nivolumab, or pembrolizumab should not be used in the adjuvant setting for patients with stage II or III colon cancer outside the setting of a clinical trial. COL-4
Development of therapeutic antibodies for the treatment of ...
jbiomedsci.biomedcentral.comRamucirumab Cyramza Eli Lilly/ImClone Systems Inc. VEGFR2 Human IgG1 Phage display Gastric cancer 2014 Vedolizumab Entyvio Genentech Inc./Millennium Pharmaceuticals Inc./Takeda Pharmaceuticals U.S.A. Inc. α4β7 integrin Humanized IgG1 Hybridoma Ulcerative colitis, Crohn disease 2014 Blinatumomab Blincyto Amgen CD19, CD3 Murine bispecific ...
Procedures, programs and drugs that require …
www.aetna.com(ramucirumab) Danyelza (naxitamab-gqgk) — precertification required effective 3/1/2021 Darzalex (daratumumab) Proprietary . Humatrope* (somatropin) precertification hyaluronidase-oysk) Herzuma (trastuzumab-pkrb) Darzalex Faspro (daratumumab and …
LILLY CARES FOUNDATION Patient Assistance Program …
www.lillycares.comAlimta® (pemetrexed for injection) Cyramza® (ramucirumab) injection Erbitux® (cetuximab) injection Portrazza® (necitumumab) injection Retevmo® (selpercatinib) capsules Verzenio® (abemaciclib) tablets Who qualifies for the Lilly Cares Program? To qualify, you must meet the requirements listed below:
CANCER DRUG PHARMACOLOGY TABLE
www.bccancer.bc.caramucirumab (VEGFR2 and VEGF A, C, and D) regorafenib (VEGFR-1, -2, & -3, TIE2, KIT, RET RAF-1, BRAF, BRAV600E, PDGFR, FGFR) ribociclib (CDK 4/6) rituximab (CD20) ruxolitinib (JAK 1 & 2) sacituzumab govitecan (IgG1.k antibody conjugated with cytotoxic) siltuximab (IL-6) Sonidegib (Hh) sorafinib (c-Raf,b-Raf, V600E,b-Raf,KIT,FLT-3,
RAINBOW - jgca.jp
www.jgca.jpRamucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicenter placebo-controlled, phase 3 trial